Immatics N.V. (IMTX): Price and Financial Metrics
IMTX Price/Volume Stats
|Current price||$11.27||52-week high||$13.14|
|Prev. close||$11.01||52-week low||$5.90|
|Day high||$11.50||Avg. volume||357,053|
|50-day MA||$12.02||Dividend yield||N/A|
|200-day MA||$9.77||Market Cap||864.08M|
IMTX Stock Price Chart Interactive Chart >
IMTX POWR Grades
- Value is the dimension where IMTX ranks best; there it ranks ahead of 63.43% of US stocks.
- IMTX's strongest trending metric is Value; it's been moving down over the last 178 days.
- IMTX's current lowest rank is in the Momentum metric (where it is better than 5.45% of US stocks).
IMTX Stock Summary
- IMTX's price/sales ratio is 11.05; that's higher than the P/S ratio of 90.09% of US stocks.
- In terms of twelve month growth in earnings before interest and taxes, IMMATICS NV is reporting a growth rate of -483.26%; that's higher than merely 3.37% of US stocks.
- Revenue growth over the past 12 months for IMMATICS NV comes in at -36.79%, a number that bests just 6.79% of the US stocks we're tracking.
- Stocks that are quantitatively similar to IMTX, based on their financial statements, market capitalization, and price volatility, are CCCC, PRTA, VIR, RCUS, and ACRS.
- Visit IMTX's SEC page to see the company's official filings. To visit the company's web site, go to www.immatics.com.
Immatics N.V. (IMTX) Company Bio
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct therapeutic modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors; and IMA204, an anti-tumor therapy that targets the malignant tumor cell. Its TCR Bispecifics product candidates include IMA401, a cancer testis antigen for the treatment of solid tumor; and IMA402 for the treatment of solid and hematological malignancies. The company also develops IMA101, a multi-target precision immunotherapy; and IMA301, an off-the-shelf ACT. It has a strategic collaboration agreement with GlaxoSmithKline plc to develop novel adoptive cell therapies targeting multiple cancer indications; MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers; Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications; Amgen Inc.; and MorphoSys to develop novel antibody-based therapies against various cancer antigens that are recognized by T cells. Immatics N.V. is headquartered in TÃ¼bingen, Germany.
IMTX Latest News Stream
|Loading, please wait...|
IMTX Latest Social Stream
View Full IMTX Social Stream
Latest IMTX News From Around the Web
Below are the latest news stories about IMMATICS NV that investors may wish to consider to help them evaluate IMTX as an investment opportunity.
Immatics N.V. (NASDAQ:IMTX) is definitely on the radar of institutional investors who own 47% of the company
Key Insights Significantly high institutional ownership implies Immatics' stock price is sensitive to their trading...
Protalix BioTherapeutics Appoints Eliot Richard Forster, Ph.D. as Chairman of its Board of Directors
Appointment effective as of September 14, 2023;Zeev Bronfeld to retire from the Board of Directors
Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics
Moderna, Inc. (NASDAQ:MRNA, "Moderna") and Immatics N.V. (NASDAQ:IMTX, "Immatics"), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced a strategic research and development collaboration to pioneer novel and transformative therapies for cancer patients with high unmet medical need.
By buying an index fund, you can roughly match the market return with ease. But if you pick the right individual...
Phase 1/2 clinical trial initiated evaluating Immatics’ second next-generation half-life extended TCR Bispecific program, TCER® IMA402 targeting PRAMEACTengine® IMA203 TCR-T monotherapy against PRAME showed 67% confirmed ORR in an interim clinical update on 11 heavily pre-treated patients in Phase 1b dose expansion Cohort A with median duration of response not reached at a median follow-up time of 8.5 months at data cut-off; next update in 4Q 2023Bristol Myers Squibb exercised first opt-in into
IMTX Price Returns